TB Alliance is Honored to Accept the Prix Galien Award for Best Pharmaceutical Agent
NEW YORK (October 30, 2020)—At the Prix Galien Awards Ceremony on Thursday, October 29, The Galien Foundation named pretomanid the Best Pharmaceutical Agent of 2019.
“This would not have been possible without the strong support and commitment of all our partners, donors, and, above all, the participants in our clinical trials,” said Mel Spigelman, MD, president and CEO of TB Alliance, during the Prix Galien Awards Ceremony. “They are the true heroes of this accomplishment. We cannot thank them enough for their contribution to ending TB.”
In 2019, TB Alliance’s anti-TB drug pretomanid received its first regulatory approval as part of a three-drug, six-month, all-oral regimen for people with highly resistant forms of TB. This regimen is known as “BPaL” and includes the drugs bedaquiline, pretomanid and linezolid. Pretomanid is only the third new medicine for drug-resistant TB to be approved by a stringent regulatory authority in the past 40 years and the first to be developed and registered by a non-profit organization.1,2
In 2005, during the first outbreak of extensively drug-resistant TB (XDR-TB) in KwaZulu-Natal, South Africa, 52 of 53 people who contracted the disease died. According to results published in the New England Journal of Medicine on March 5, 2020, the BPaL regimen, is a three-drug, six-month, all-oral treatment that has been shown to successfully treat 90% of patients.3
TB Alliance is honored to accept the Prix Galien award for Best Pharmaceutical Agent of 2019. For more information about the awards, please visit The Galien Foundation website.
Fox W. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units. Int J Tuberc Lung Dis. 1999;3(10):S231-S279.
U.S. Food and Drug Administration. Drug Approvals and Databases. Available at: https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases
Conradie F, et al. Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis. N Eng J Med 2020;382:893-902.